HRP20240331T1 - Lijek za liječenje infektivnih bolesti - Google Patents
Lijek za liječenje infektivnih bolesti Download PDFInfo
- Publication number
- HRP20240331T1 HRP20240331T1 HRP20240331TT HRP20240331T HRP20240331T1 HR P20240331 T1 HRP20240331 T1 HR P20240331T1 HR P20240331T T HRP20240331T T HR P20240331TT HR P20240331 T HRP20240331 T HR P20240331T HR P20240331 T1 HRP20240331 T1 HR P20240331T1
- Authority
- HR
- Croatia
- Prior art keywords
- infection
- antibodies
- drug
- bacterial
- antibiotic
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 19
- 208000035473 Communicable disease Diseases 0.000 title claims 3
- 229940079593 drug Drugs 0.000 claims 18
- 230000003115 biocidal effect Effects 0.000 claims 8
- 238000013207 serial dilution Methods 0.000 claims 8
- 239000000126 substance Substances 0.000 claims 7
- 208000035143 Bacterial infection Diseases 0.000 claims 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims 5
- 238000010790 dilution Methods 0.000 claims 5
- 239000012895 dilution Substances 0.000 claims 5
- 208000015181 infectious disease Diseases 0.000 claims 5
- 108010039343 HLA-DRB1 Chains Proteins 0.000 claims 4
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- 229940088710 antibiotic agent Drugs 0.000 claims 4
- 230000001580 bacterial effect Effects 0.000 claims 4
- 208000003322 Coinfection Diseases 0.000 claims 3
- 108010074328 Interferon-gamma Proteins 0.000 claims 3
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 3
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 claims 2
- 102100037850 Interferon gamma Human genes 0.000 claims 2
- 206010022678 Intestinal infections Diseases 0.000 claims 2
- 241000588747 Klebsiella pneumoniae Species 0.000 claims 2
- 102000043131 MHC class II family Human genes 0.000 claims 2
- 108091054438 MHC class II family Proteins 0.000 claims 2
- 206010039438 Salmonella Infections Diseases 0.000 claims 2
- 206010061372 Streptococcal infection Diseases 0.000 claims 2
- 201000003146 cystitis Diseases 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 201000007094 prostatitis Diseases 0.000 claims 2
- 206010039447 salmonellosis Diseases 0.000 claims 2
- 206010040872 skin infection Diseases 0.000 claims 2
- 239000007909 solid dosage form Substances 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 208000019206 urinary tract infection Diseases 0.000 claims 2
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 206010034133 Pathogen resistance Diseases 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 claims 1
- 206010035737 Pneumonia viral Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 1
- 229940041033 macrolides Drugs 0.000 claims 1
- 150000002960 penicillins Chemical class 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 208000009421 viral pneumonia Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Claims (15)
1. Lijek, koji predstavlja tehnološki obrađen proizvod koji je rezultat višestrukih serijskih razrjeđenja osnovnih supstanci antitijela na β1 domenu molekule glavnog kompleksa histokompatibilnosti klase II (HLA-DRB1) i na β2-mikroglobulin (β2-MG); pri čemu su višestruka serijska razrjeđenja decimalna, centezimalna i milezimalna razrjeđenja u bilo kojim odnosima razrjeđenja; i pri čemu su osnovne supstance u koncentraciji od 0.5 - 5.0 mg/ml.
2. Lijek prema patentnom zahtjevu 1 za liječenje bakterijskih infekcija; izborno pri čemu je bakterijska infekcija (i) uzrokovana bakterijama otpornim na jedan ili više poznatih antibiotika; (ii) infekcija urinarnog trakta izabrana od cistitisa i prostatitisa; (iii) je bakterijska crijevna infekcija; (iv) bakterijska infekcija kože; (v) tuberkuloza; ili (vii) izabrana od salmoneloze, infekcije E. coli, streptokokne infekcije i Klebsiella pneumoniae.
3. Lijek prema patentnom zahtjevu 1, naznačen time što su antitijela monoklonska, poliklonska ili prirodna.
4. Lijek prema patentnom zahtjevu 1, formuliran kao čvrsti dozni oblik, koji sadrži efikasne količine neutralnih granula nosača impregniranih tehnološki obrađenim proizvodom koji je rezultat višestrukih serijskih razrjeđenja osnovnih supstanci antitijela na HLA DRB1 i antitijela na β2-mikroglobulin, kao i farmaceutski prihvatljive ekscipijense.
5. Kombinacija antibiotika i lijeka prema bilo kojem od patentnih zahtjeva 1 do 4, za istovremenu ili uzastopnu primjenu za liječenje bakterijskih infekcija; izborno pri čemu je bakterijska infekcija (i) uzrokovana bakterijama otpornim na jedan ili više poznatih antibiotika; (ii) infekcija urinarnog trakta izabrana od cistitisa i prostatitisa; (iii) je bakterijska crijevna infekcija; (iv) bakterijska infekcija kože; (v) tuberkuloza; ili (vii) izabrana od salmoneloze, infekcije E. coli, streptokokne infekcije i Klebsiella pneumoniae.
6. Antibiotik i lijek prema patentnom zahtjevu 1 za uporabu u postupku smanjenja rezistencije bakterija na antibiotsku terapiju, koji sadrži istovremenu ili uzastopnu ko-primjenu antibiotika i lijeka prema patentnom zahtjevu 1.
7. Antibiotik i lijek za uporabu prema patentnom zahtjevu 6, naznačeni time što se antibiotik primjenjuje u poznatoj efikasnoj dozi.
8. Lijek prema patentnom zahtjevu 1 za uporabu u postupku za pojačanje efikasnosti antibiotika, koji sadrži istovremeno ili uzastopno primjenjivanje lijeka prema patentnom zahtjevu 1.
9. Kombinacija prema patentnom zahtjevu 5, antibiotik i lijek za uporabu prema patentnom zahtjevu 6 ili lijek za uporabu prema patentnom zahtjevu 8; naznačeni time što je antibiotik izabran iz klase penicilina, aminoglikozida, makrolida i oksazolidinona.
10. Lijek za uporabu prema patentnom zahtjevu 8, naznačen time što se antibiotik primjenjuje u 50% efikasne doze (ED50).
11. Lijek, koji predstavlja tehnološki obrađen proizvod koji je rezultat višestrukih serijskih razrjeđenja osnovnih supstanci a) antitijela na β1 domenu molekule glavnog kompleksa histokompatibilnosti klase II (HLA-DRB1), b) antitijela na β2-mikroglobulin β2-MG), c) antitijela na interferon gama (IFN-γ) i d) antitijela na CD4; pri čemu su višestruka serijska razrjeđenja decimalna, centezimalna i milezimalna razrjeđenja u bilo kojim odnosima razrjeđenja; i pri čemu su osnovne supstance u koncentraciji od 0.5 - 5.0 mg/ml.
12. Lijek prema patentnom zahtjevu 11 za liječenje infektivnih bolesti; izborno pri čemu infektivna bolest je (i) virusna infekcija; izborno izabrana od URI, gripa; (ii) bakterijska infekcija; (iii) miješana infekcija (iv) sekundarna infekcija; izborno pri čemu je sekundarna infekcija virusna/bakterijska pneumonija.
13. Lijek prema patentnom zahtjevu 1 ili patentnom zahtjevu 11, naznačen time što tehnološki obrađen proizvod koji je rezultat višestrukih serijskih razrjeđenja osnovne supstance antitijela je vodena ili vodeno-alkoholna otopina dobiven iz serijskih razrjeđenja matrične otopine antitijela, uz ponovljeno mućkanje svakog razrjeđenja; izborno pri čemu se matrična otopina antitijela koristi u koncentraciji od 0.5 - 5.0 mg/ml.
14. Lijek prema bilo kojem od patentnih zahtjeva 11 do 13, naznačen time što su antitijela monoklonska, poliklonska ili prirodna.
15. Lijek prema patentnom zahtjevu 11 formuliran kao čvrst dozni oblik, koji sadrži efikasne količine neutralnih nosećih granula impregniranih tehnološki obrađenim proizvodom koji je rezultat višestrukih serijskih razrjeđenja osnovnih supstanci antitijela na HLA DRB1, antitijela na β2-MG, antitijela na IFN-γ i antitijela na CD4 kao i farmaceutski prihvatljive ekscipijense.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2019127185A RU2778521C2 (ru) | 2019-08-29 | Лекарственное средство для лечения бактериальных инфекций | |
| RU2019127186A RU2778522C2 (ru) | 2019-08-29 | Лекарственное средство для лечения инфекционных заболеваний | |
| PCT/RU2020/050193 WO2021040570A1 (en) | 2019-08-29 | 2020-08-19 | Medicament and method for treating infectious diseases |
| EP20800353.3A EP4021505B1 (en) | 2019-08-29 | 2020-08-19 | Medicament for treating infectious diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240331T1 true HRP20240331T1 (hr) | 2024-06-07 |
Family
ID=73040208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240331TT HRP20240331T1 (hr) | 2019-08-29 | 2020-08-19 | Lijek za liječenje infektivnih bolesti |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220213197A1 (hr) |
| EP (1) | EP4021505B1 (hr) |
| JP (1) | JP2022545178A (hr) |
| CN (1) | CN114375200A (hr) |
| BR (1) | BR112022001472A2 (hr) |
| DK (1) | DK4021505T3 (hr) |
| ES (1) | ES2973183T3 (hr) |
| FI (1) | FI4021505T3 (hr) |
| HR (1) | HRP20240331T1 (hr) |
| HU (1) | HUE065591T2 (hr) |
| MX (1) | MX2022000536A (hr) |
| PL (1) | PL4021505T3 (hr) |
| PT (1) | PT4021505T (hr) |
| RS (1) | RS65255B1 (hr) |
| SI (1) | SI4021505T1 (hr) |
| WO (1) | WO2021040570A1 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117771379B (zh) * | 2023-10-25 | 2024-08-30 | 珠海泰诺麦博制药股份有限公司 | 特异性结合金黄色葡萄球菌Hla毒素的全人源抗体与抗生素的组合 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2181297C2 (ru) * | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| RU2197266C1 (ru) * | 2001-06-01 | 2003-01-27 | Эпштейн Олег Ильич | Лекарственное средство и способ лечения эрозивных и воспалительных заболеваний желудочно-кишечного тракта |
| RU2205025C1 (ru) | 2001-12-26 | 2003-05-27 | Гольдберг Евгений Данилович | Способ коррекции иммунного ответа и лекарственное средство |
| RU2309732C1 (ru) * | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
| RU2363470C1 (ru) | 2007-12-26 | 2009-08-10 | Государственное образовательное учреждение высшего профессионального образования Самарский государственный медицинский университет | Способ преодоления лекарственной устойчивости бактерий и грибов |
| EP2593477A2 (en) * | 2010-07-15 | 2013-05-22 | Oleg Iliich Epshtein | Pharmaceutical compositions and methods of treatment |
| PE20130397A1 (es) * | 2010-07-15 | 2013-04-10 | Oleg Iliich Epshtein | Composicion farmaceutica combinada y metodos para el tratamiento de las enfermedades o condiciones funcionales del tracto gastrointestinal |
| RU2500422C2 (ru) | 2010-08-06 | 2013-12-10 | Олег Ильич Эпштейн | Комплексное лекарственное средство для лечения вирусных инфекций и способ лечения вирусных инфекций |
| RU2521392C2 (ru) | 2010-08-06 | 2014-06-27 | Олег Ильич Эпштейн | Комплексное лекарственное средство для лечения вирусных заболеваний и способ лечения вирусных заболеваний |
| BR112013002296A2 (pt) * | 2010-08-06 | 2018-01-30 | Lliich Epshtein Oleg | composição farmacêutica e respectivo uso e método para tratar doença infecciosa |
| RU2655808C2 (ru) | 2016-10-11 | 2018-05-29 | Закрытое Акционерное Общество "Биологические Исследования И Системы" (Зао "Бис") | Фармацевтическая комбинированная композиция для местного и наружного применения на основе бактериолитического и протеолитического комплекса ферментов |
-
2020
- 2020-08-19 MX MX2022000536A patent/MX2022000536A/es unknown
- 2020-08-19 PL PL20800353.3T patent/PL4021505T3/pl unknown
- 2020-08-19 WO PCT/RU2020/050193 patent/WO2021040570A1/en active Application Filing
- 2020-08-19 JP JP2022506768A patent/JP2022545178A/ja not_active Withdrawn
- 2020-08-19 ES ES20800353T patent/ES2973183T3/es active Active
- 2020-08-19 HU HUE20800353A patent/HUE065591T2/hu unknown
- 2020-08-19 US US17/608,270 patent/US20220213197A1/en active Pending
- 2020-08-19 PT PT208003533T patent/PT4021505T/pt unknown
- 2020-08-19 CN CN202080060725.3A patent/CN114375200A/zh active Pending
- 2020-08-19 EP EP20800353.3A patent/EP4021505B1/en active Active
- 2020-08-19 SI SI202030365T patent/SI4021505T1/sl unknown
- 2020-08-19 HR HRP20240331TT patent/HRP20240331T1/hr unknown
- 2020-08-19 RS RS20240275A patent/RS65255B1/sr unknown
- 2020-08-19 FI FIEP20800353.3T patent/FI4021505T3/fi active
- 2020-08-19 BR BR112022001472A patent/BR112022001472A2/pt unknown
- 2020-08-19 DK DK20800353.3T patent/DK4021505T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| HUE065591T2 (hu) | 2024-06-28 |
| EP4021505B1 (en) | 2023-12-13 |
| US20220213197A1 (en) | 2022-07-07 |
| RS65255B1 (sr) | 2024-03-29 |
| WO2021040570A1 (en) | 2021-03-04 |
| JP2022545178A (ja) | 2022-10-26 |
| MX2022000536A (es) | 2022-02-10 |
| BR112022001472A2 (pt) | 2022-03-22 |
| CN114375200A (zh) | 2022-04-19 |
| FI4021505T3 (fi) | 2024-03-01 |
| EP4021505A1 (en) | 2022-07-06 |
| PL4021505T3 (pl) | 2024-06-24 |
| DK4021505T3 (da) | 2024-02-12 |
| ES2973183T3 (es) | 2024-06-18 |
| PT4021505T (pt) | 2024-03-11 |
| SI4021505T1 (sl) | 2024-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ioannidis | Indirect comparisons: the mesh and mess of clinical trials | |
| Hartmann et al. | Treatment of cats with feline infectious peritonitis | |
| Wang et al. | Intravenous immunoglobulin replacement therapy to prevent pulmonary infection in a patient with Good's syndrome | |
| RU2010133045A (ru) | Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида | |
| CN103933086A (zh) | 一种含穿心莲和阿米卡星的畜禽用复方药物 | |
| HRP20240331T1 (hr) | Lijek za liječenje infektivnih bolesti | |
| CN103977089B (zh) | 一种含有赤芍和磷霉素的畜禽用复方药物 | |
| Deveikis et al. | Antimicrobial therapy of experimental group B streptococcal infection in mice | |
| CN103127508B (zh) | 一种含有泽兰治疗畜禽大肠杆菌感染疾病的复方组合物 | |
| Wierda et al. | Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): Results from a randomized, multicenter, international, two-dose, parallel group, phase II trial. | |
| Paradisi et al. | Infections in multiple myeloma | |
| Orfanakis et al. | In vitro studies of the combined effect of ampicillin and sulfonamides on Nocardia asteroides and results of therapy in four patients | |
| Elneil et al. | Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab | |
| RU2011127226A (ru) | Способ лечения инфекционных заболеваний и комплексное лекарственное средство для лечения инфекционных заболеваний | |
| Champawat et al. | Effect of flunixin co-administration on pharmacokinetics of cefquinome following intramuscular administration in goats | |
| CN104027370B (zh) | 一种含有白花丹和痢菌净的畜禽用复方组合物 | |
| Cohen | Emerging problems of antimicrobial resistance | |
| JPWO2021040570A5 (hr) | ||
| RU2019127185A (ru) | Лекарственное средство и способы лечения бактериальных инфекций | |
| RU2778522C2 (ru) | Лекарственное средство для лечения инфекционных заболеваний | |
| RU2013150335A (ru) | Применение секнидазола для лечения одонтогенных инфекций | |
| Saha et al. | Antimicrobials in Growth and Development | |
| RU2010107301A (ru) | Способ лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностного антигена h5n1, и лекарственное средство для лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностного антигена h5n1 | |
| Aronin | Current pharmacotherapy of pneumococcal meningitis | |
| Miura et al. | Clinical Significance of Arbekacin Sulfate for High-Risk Infections Among Patients with Hematological Malignancies |